2. Signaling Pathways
  3. GPCR/G Protein
  4. Angiotensin Receptor
  5. AT2 Receptor Isoform
  6. AT2 Receptor Antagonist

AT2 Receptor Antagonist

AT2 Receptor Antagonists (12):

Cat. No. Product Name Effect Purity
  • HY-P0216
    A 779
    		Antagonist 98.59%
    A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an Ang1-7 receptor distinct from the classical AngII.
  • HY-10259A
    PD 123319 ditrifluoroacetate
    		Antagonist 99.82%
    PD 123319 (ditrifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
  • HY-119544
    Ripisartan
    		Antagonist
    Ripisartan (UP-2696) is an angiotensin II receptor antagonist. Ripisartan is orally available. Ripisartan binds to angiotensin II receptors, dilates blood vessels, and lowers blood pressure.
  • HY-123226
    TA-606
    		Antagonist
    TA-606 is a potent and orally active angiotensin II-receptor antagonist. TA-606 shows antihypertensive efficacy. TA-606 can be used for hypertension research.
  • HY-19202
    rac-Olodanrigan
    		Antagonist
    rac-Olodanrigan (rac-EMA401; EMA400) is a racemic mixture of the S-enantiomer (EMA401; HY-13106) and R-enantiomer (EMA402). rac-Olodanrigan is a potent and selective AT2 receptor antagonist with IC50s of 75.2 nM and 2918 nM for AT2R and AT1R, respectively. rac-Olodanrigan evokes dose-dependent relief of mechanical allodynia in the ipsilateral hind paws of rats with a chronic constriction injury (CCI) of the sciatic nerve.
  • HY-13106
    Olodanrigan
    		Antagonist 98.55%
    Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
  • HY-12405
    CGP-42112
    		Antagonist 99.23%
    CGP-42112 (CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist.
  • HY-19732
    BIBS 39
    		Antagonist 99.70%
    BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.
  • HY-13106A
    Olodanrigan sodium
    		Antagonist
    Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
  • HY-146410
    AT2R antagonist 1
    		Antagonist
    AT2R antagonist 1 (compound 21) is a potent and high selective AT2R (angiotensin II AT2 receptor) ligand. AT2R antagonist 1 exhibits a fair AT2R affinity, with a Ki of 29 nM. AT2R antagonist 1 also inhibits common agent-metabolizing CYP enzymes. AT2R antagonist 1 shows high stability in human, rat and mouse liver microsomes.
  • HY-117858
    CL-329167
    		Antagonist
    CL-329167 (compound 12) is an orally active and competitive angiotensin II receptor antagonist (IC50=6 nM). CL-329167 can be used in the research of hypertension.
  • HY-121767
    PD 123177
    		Antagonist
    PD 123177 is a nonpeptide antagonist specific for angiotensin II (AII) subtype AT2 receptor in mammalian systems.